Abuse-Deterrent Exemption From Medicaid Rebates Hinges On FDA Standards
Executive Summary
Opioid formulations with abuse-deterrent properties will be exempt from Medicaid price-inflation rebates if they meet FDA standards, Centers for Medicare and Medicaid Services says in guidance to manufacturers.
You may also be interested in...
Medicaid Rebates To Increase $3.95bn With Revision For Line Extensions
CMS issues interim final rule to ensure there’s ‘no confusion’ that line extensions are now subject to higher Medicaid rebate requirements.
Abuse-Deterrent Formulations Exempt From Medicaid Rebates Under Bill
Comprehensive opioid addiction legislation is considered by House-Senate conference committee on July 6.
Medicaid Add-On Rebates For Line Extensions Remain A Judgment Call
Manufacturers must continue to use their discretion on which line extensions should be subject to inflation-based Medicaid rebates in lieu of guidance from CMS in its recent AMP final rule.